Follicular Lymphoma

>

Latest News

Mature Data Confirm Benefit of Early Rituximab vs Watchful Waiting in Asymptomatic Follicular Lymphoma
Mature Data Confirm Benefit of Early Rituximab vs Watchful Waiting in Asymptomatic Follicular Lymphoma

May 22nd 2025

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no added benefit over induction alone.

FDA Accepts Odronextamab BLA in Relapsed/Refractory Follicular Lymphoma
FDA Accepts Odronextamab BLA in Relapsed/Refractory Follicular Lymphoma

February 26th 2025

Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?

November 5th 2024

Exploring Bispecific Antibodies and Targeted Approaches in Follicular Lymphoma
Exploring Bispecific Antibodies and Targeted Approaches in Follicular Lymphoma

September 4th 2024

Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point

August 16th 2024

Video Series
Video Interviews

More News